FDA Letter API

K & B Company Inc.

Letter data

Company
K & B Company Inc.
Recipient
Brent A. Bischoff | President | K & B Company Inc. | K & B Company Inc. | 109 Arnold St. | Gallup | , | NM | 87301 | United States
Issue date
2018-09-12
Posted date
Not available
FDA office
Office of Human and Animal Foods-Division IV West
Subject
Not available
Product
Not available
CMS ID
528522
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER K & B Company Inc. MARCS-CMS 528522 — September 12, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: UPS Overnight Recipient: Recipient Name Brent A. Bischoff Recipient Title President K & B Company Inc. K & B Company Inc. 109 Arnold St. Gallup , NM 87301 United States Issuing Office: Office of Human and Animal Foods-Division IV West United States September 12, 2018 WARNING LETTER CLOSE-OUT VIA UPS overnight Brent A. Bischoff President K & B Company Inc. 109 Arnold St. Gallup, NM 87301 Dear Mr. Bischoff: The Food and Drug Administration has completed an evaluation of K & B Company's corrective actions in response to our Warning Letter HAF4W(DEN)-17-09-WL (DR) dated July 5, 2017. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ LaTonya M. Mitchell District Director, FDA Denver District Program Division Director Office of Human and Animal Foods - Division IV West Content current as of: 10/01/2018